Prostate CancerMultiparametric Magnetic Resonance Imaging (MRI) and MRI–Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen
Introduction
Multiparametric magnetic resonance imaging (mpMRI) and fusion targeted biopsies (FTBs) of the prostate have demonstrated excellent detection of significant prostate cancer (sPCa) while mitigating diagnosis of insignificant PCa [1], [2]. The growing impact of mpMRI is supported by a standardized reporting system, Prostate Imaging Reporting and Data System (PI-RADS) [3], [4].
The question of whether FTB alone should be performed is under debate [1], [5], [6], [7], [8]. Although Siddiqui et al [1] and Rastinehad et al [5] described that FTB using MRI and transrectal ultrasound (TRUS) fusion misses only approximately 5% of sPCa, Le et al [6] reported that 17% of sPCas were missed by fusion biopsy, suggesting use of a combined FTB and 12-core systematic biopsy to obtain best predictive accuracy. Aiming for detection of all sPCa, transperineal grid–directed template mapping techniques have been introduced [9]. Using transperineal saturation biopsy (SB) as a reference test, our group demonstrated that FTB missed 15% of Gleason score (GS) ≥3 + 4 PCa [7]. Thus, the combination of FTB and SB seems to be appropriate to achieve a maximally accurate biopsy [7]. However, due to variability in study methodology, only a correlation analysis of mpMRI, FTB and radical prostatectomy (RP) specimen may assess the rate of sPCa foci that are missed by mpMRI and different biopsy approaches [10]. Rosenkrantz et al reported a positive predictive value (PPV) for an exact match between suspicious lesions on MRI and whole-mount sections of 65% [11]. Turkbey et al observed sensitivity of 80% for the detection of sPCa and 94% for sPCa in the peripheral zone [12]. In the PI-RADS era, Baco et al found that the location of the index lesion was correctly assessed by MRI in 95% of patients [13]. Although Delongchamps et al [14] demonstrated that mpMRI missed 10% sPCa on a per-lesion basis but no sPCa on a per-patient basis, Le et al [15] analyzed multifocality and reported that mpMRI missed 20% of index lesions.
The first objective of our study was to evaluate the performance of mpMRI and different biopsy approaches to detect index lesions and sPCa in an RP specimen. Second, we characterized missed tumor foci. Because recent publications demonstrate that tumor volume (TV) might be important to characterize sPCa, we also analyzed TV differences between mpMRI and RP [13], [16].
Section snippets
Study population
Consecutive patients were registered into a prospective institutional review board–approved database (S011/2011) assessing MRI-targeted prostate biopsy at University Hospital Heidelberg between October 2012 and September 2014. Subgroups of this cohort were reported previously [7].
Inclusion criteria for the present study were mpMRI with PI-RADS scoring, MRI/TRUS fusion biopsy, and RP at our department. Pretreated patients were excluded from the analysis, which was done retrospectively.
Imaging
All mpMRI
Results
A total of 755 patients underwent mpMRI and subsequent MRI/TRUS fusion biopsy between 2012 and 2014. Of 489 PCa-positive patients, 120 men with subsequent RP were included in the analysis. Patient selection is described in Supplementary Figure 1. Patient demographics, mpMRI, and biopsy statistics according to the Standards of Reporting for MRI-targeted Biopsy Studies (START) are listed in Table 1 [24]. RP results are given in Supplementary Table 3.
Descriptive results concerning index and
Discussion
The potential of MRI/TRUS fusion biopsy to detect sPCa is influenced by several issues. First, correct index lesion detection by mpMRI occurred in 92% of patients and was comparable to recent publications [13], [14], [15]. Taking multifocal PCa into account, the detection rate of all sPCa lesions was 85%. Similar to results by Le et al, mpMRI missed 86% of nonsignificant nonindex lesions [15]. Compared with combined SB and FTB, detection of all sPCa lesions by mpMRI was significantly inferior
Conclusions
MpMRI detected the index lesion accurately in 92%; however, TV was underestimated, and detection of all sPCa was limited to 85% in case of multifocality. Based on the results of our audit, FTB alone misses a small number of significant index lesions. The combination of mpMRI, FTB, and SB finds more significant cancer than any single modality; however, the addition of SB comes at the cost of detecting more low-risk cancer.
References (30)
- et al.
MRI-ultrasound fusion biopsy for prediction of final prostate pathology
J Urol
(2014) - et al.
Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance
J Urol
(2015) - et al.
randomized controlled trial to assess and compare the outcomes of two-core prostate biopsy guided by fused magnetic resonance and transrectal ultrasound images and traditional 12-core systematic biopsy
Eur Urol
(2016) - et al.
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review
Eur Urol
(2013) - et al.
Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients
Eur Urol
(2015) - et al.
Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology
Eur Urol
(2015) - et al.
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial
J Urol
(2011) - et al.
A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion
J Urol
(2011) - et al.
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume
Mod Pathol
(2011) - et al.
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting
Eur Urol
(2011)